RxDoctor Payments Data

Nicole Patterson

Family · Cambridge City, INNPI 1871139014

Payments from drug & device makers

$1,205in general payments, 2019–2025

Across 56 payments — averaging $21.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Hologic Sales And Service, LLC$269
  • Esperion Therapeutics, Inc.$196
  • Boehringer Ingelheim$175
  • Gilead$125
  • Pfizer$65
  • AbbVie$55
  • plus $319 from 15 others

What the payments were for

  • Food & beverage$1,205100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,205 in reported general payments places this provider in the 70th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$2,108
Medicare patients
75
Services billed
204

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide84$85,564
Trelegy ElliptaFluticasone/Umeclidin/Vilanter51$33,859
JardianceEmpagliflozin32$32,602
TrulicityDulaglutide16$22,420
MyrbetriqMirabegron25$15,457
EliquisApixaban14$11,784
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$11,378
FarxigaDapagliflozin Propanediol14$10,381
Eletriptan HbrEletriptan Hydrobromide12$5,776
Lantus SolostarInsulin Glargine,hum.Rec.Anlog32$5,545
RestasisCyclosporine11$5,079
Fluticasone-SalmeterolFluticasone Propion/Salmeterol36$4,754
Albuterol Sulfate HfaAlbuterol Sulfate117$4,190
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen230$3,219
Varenicline Tartrate12$2,970

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$34$85,56484 claims
GSKTrelegy Ellipta$27$33,85951 claims
Boehringer IngelheimJardiance$175$32,60232 claims
PfizerEliquis$65$11,78414 claims
AbbVieRestasis, Synthroid$55$6,30628 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,392 family providers in Indiana.

Other family in Cambridge City

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →